Jazz Pharmaceuticals plc Deferred Revenue Recognized
Jazz Pharmaceuticals plc (JAZZ) reported Deferred Revenue Recognized of $2.09 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2023-03-01
- Jazz Pharmaceuticals plc contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was $523.00K, a 17.77% decline year-over-year.
- Jazz Pharmaceuticals plc contract with customer, liability, revenue recognized for the quarter ending 2021-03-31 was $636.00K, a 46.10% decline year-over-year.
- Jazz Pharmaceuticals plc contract with customer, liability, revenue recognized for the quarter ending 2020-03-31 was $1.18M, a 37.03% decline year-over-year.
- Jazz Pharmaceuticals plc contract with customer, liability, revenue recognized for the quarter ending 2019-03-31 was $1.87M, a 0.05% decline year-over-year.
- Jazz Pharmaceuticals plc contract with customer, liability, revenue recognized for fiscal 2022 was $2.09M, a 24.93% decline from fiscal 2021.
- Jazz Pharmaceuticals plc contract with customer, liability, revenue recognized for fiscal 2021 was $2.79M, a 40.93% decline from fiscal 2020.
- Jazz Pharmaceuticals plc contract with customer, liability, revenue recognized for fiscal 2020 was $4.72M, a 12.82% decline from fiscal 2019.
- Jazz Pharmaceuticals plc contract with customer, liability, revenue recognized for fiscal 2019 was $5.41M, a 27.79% decline from fiscal 2018.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2022-12-31 | $2.09M 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $1.57M 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $1.05M 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $523.00K 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | $2.79M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $2.09M 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $1.39M 10-Q · filed 2021-08-03 | |||
| 2021-03-31 | $636.00K 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $4.72M 10-K · filed 2021-02-23 | |||
| 2020-09-30 | $3.54M 10-Q · filed 2020-11-02 | |||
| 2020-06-30 | $2.36M 10-Q · filed 2020-08-04 | |||
| 2020-03-31 | $1.18M 10-Q · filed 2020-05-05 | |||
| 2019-12-31 | $5.41M 10-K · filed 2020-02-25 | |||
| 2019-09-30 | $4.23M 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | $3.05M 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $1.87M 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $7.50M 10-K · filed 2019-02-26 | |||
| 2018-09-30 | $5.62M 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $3.75M 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $1.88M 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |